CircRNAs have the potential to aid in the diagnosis and treatment of lipid diseases

Abstract

CircRNAs have the potential to aid in the diagnosis and treatment of lipid diseases, and further study and development is needed in the future. Further advancements, for example, are required in disease-oriented critical circRNA screening technology, which can analyze differentially expressed circRNAs in different tissues and screen out the key circRNAs, providing valuable biomarkers for diagnosis or targets to treat lipid disorder diseases. We need to figure out how to modulate circRNA expression upstream, such as biogenesis and decay, or how to directly upregulate or downregulate certain circRNA expression, setting the framework for clinical intervention in certain critical circRNA in the etiology of certain lipid disorders illness. Understanding the principles governing circRNAsponging mciroRNAs is critical because it will aid in the development of new nucleic acid treatments for lipid diseases.Engineered circRNA with bulged miRNA binding sites effectively sponged the miRNA132/212 family and attenuated myocardial hypertrophy with a low dosage requirement, extended half-lives, high efficiency, and stability when compared to the antagomir, suggesting that it has exciting potential as a novel therapeutic tool. These studies will pave the way for circRNAs to be employed as diagnostic biomarkers or therapeutic targets for lipid diseases in the clinic.